Print

ASLAN Pharmaceuticals Pte Ltd and Bristol-Myers Squibb Company (BMY) Enter Innovative Partnership to License and Develop Investigational Oncology Compound  
11/3/2011 8:52:41 AM

SINGAPORE & PRINCETON, N.J.--(BUSINESS WIRE)--ASLAN Pharmaceuticals Pte Ltd, a pharmaceutical company headquartered in Singapore, and Bristol-Myers Squibb Company (NYSE: BMY) today announced an innovative strategic partnership allowing for the rapid development of BMS-777607, Bristol-Myers Squibb’s investigational small molecule inhibitor of the MET receptor tyrosine kinase for treatment of solid tumors. This creative approach will accelerate the delivery of clinical proof-of-concept by leveraging the complementary strengths of an Asia-based drug development company and a global biopharmaceutical company.